PATENT CLAIM ANALYSIS

Application Number: 15986536
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "322000"]

Abstract:
The present invention provides methods of administering a PARP inhibitor to a cancer patient.

Claim (Index 91):
A method of treating recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, comprising administering niraparib daily to a patient suffering from or at risk of recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer at an oral dose equivalent to 200 mg or 300 mg of niraparib free base.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 93.0
- Lexical Diversity: 1.07143
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15852551', '15337274', '15433249', '14772549', '14717069']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.727421950691026
- 35 USC 102 Novelty (BERT): 0.5336599478196838
- Combined Prediction Score: 0.7080457504038917
- Mean Citation Score: 324.554998
- Max Citation Score: 359.90317000000016
- Similarity Product: 249.97213309977064

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test